BARCO NV BELG ACT Earnings Calls
| Release date | Feb 10, 2026 |
| EPS estimate | - |
| EPS actual | $0.681 |
| Revenue estimate | 601.349M |
| Revenue actual | 598.413M |
| Revenue Surprise | -0.488% |
| Release date | Jul 16, 2025 |
| EPS estimate | $0.236 |
| EPS actual | $0.318 |
| EPS Surprise | 34.93% |
| Revenue estimate | 536.339M |
| Revenue actual | 535.017M |
| Revenue Surprise | -0.246% |
| Release date | May 22, 2025 |
| EPS estimate | - |
| EPS actual | $0.618 |
| Revenue estimate | - |
| Revenue actual | 530.263M |
| Release date | Oct 17, 2024 |
| EPS estimate | - |
| EPS actual | - |
| Revenue estimate | - |
| Revenue actual | - |
Last 4 Quarters for BARCO NV BELG ACT
Below you can see how BCNAF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Oct 17, 2024 |
| Price on release | $18.00 |
| EPS estimate | - |
| EPS actual | - |
| Date | Price |
|---|---|
| Oct 11, 2024 | $18.00 |
| Oct 14, 2024 | $18.00 |
| Oct 15, 2024 | $18.00 |
| Oct 16, 2024 | $18.00 |
| Oct 17, 2024 | $18.00 |
| Oct 18, 2024 | $18.00 |
| Oct 21, 2024 | $18.00 |
| Oct 22, 2024 | $18.00 |
| Oct 23, 2024 | $18.00 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | May 22, 2025 |
| Price on release | $12.90 |
| EPS estimate | - |
| EPS actual | $0.618 |
| Date | Price |
|---|---|
| May 16, 2025 | $12.90 |
| May 19, 2025 | $12.90 |
| May 20, 2025 | $12.90 |
| May 21, 2025 | $12.90 |
| May 22, 2025 | $12.90 |
| May 23, 2025 | $12.90 |
| May 26, 2025 | $12.90 |
| May 27, 2025 | $15.38 |
| May 28, 2025 | $11.50 |
| 4 days before | 0% |
| 4 days after | -10.85% |
| On release day | 0% |
| Change in period | -10.85% |
| Release date | Jul 16, 2025 |
| Price on release | $14.59 |
| EPS estimate | $0.236 |
| EPS actual | $0.318 |
| EPS surprise | 34.93% |
| Date | Price |
|---|---|
| Jul 10, 2025 | $14.59 |
| Jul 11, 2025 | $15.38 |
| Jul 14, 2025 | $14.59 |
| Jul 15, 2025 | $14.59 |
| Jul 16, 2025 | $14.59 |
| Jul 17, 2025 | $14.59 |
| Jul 18, 2025 | $15.38 |
| Jul 21, 2025 | $14.59 |
| Jul 22, 2025 | $14.59 |
| 4 days before | 0% |
| 4 days after | 0% |
| On release day | 0% |
| Change in period | 0% |
| Release date | Feb 10, 2026 |
| Price on release | $14.20 |
| EPS estimate | - |
| EPS actual | $0.681 |
| Date | Price |
|---|---|
| Feb 04, 2026 | $14.20 |
| Feb 05, 2026 | $14.20 |
| Feb 06, 2026 | $14.20 |
| Feb 09, 2026 | $14.20 |
| Feb 10, 2026 | $14.20 |
| Feb 11, 2026 | $14.20 |
| Feb 12, 2026 | $14.20 |
| Feb 13, 2026 | $12.80 |
| Feb 17, 2026 | $12.80 |
| 4 days before | 0% |
| 4 days after | -9.86% |
| On release day | 0% |
| Change in period | -9.86% |
BARCO NV BELG ACT Earnings Call Transcript Summary of Q4 2025
Barco delivered profitable growth in FY2025 with sales of EUR 964m (+2% reported, +4% constant currency) and EBITDA of EUR 125m (13% margin). Entertainment (especially Cinema and Immersive Experience) and EMEA were the main growth drivers; Cinema saw a strategic shift with HDR by Barco toward recurring revenue (total contract value of signed HDR contracts ~EUR 89m). The company managed costs tightly (OpEx down 4% year-over-year), mitigated some tariff and FX headwinds via price and footprint actions, and reported EPS of EUR 0.85 (+20%). Free cash flow was EUR 57m (6% of sales), net cash EUR 186m after returning ~EUR 120m to shareholders (dividend + buybacks); the Board proposes a higher dividend (EUR 0.55) and cancellation of ~6% of shares. For 2026 Barco expects top-line and EBITDA growth at constant currency, with growth skewed to H2 and some FX headwinds in H1; long-term targets (by 2028) of ~EUR 1.1bn revenue, 15% EBITDA and 15% recurring revenues are reconfirmed. Key risks/near-term uncertainties: U.S. market weakness (tariffs, weaker dollar, delayed government spending affecting Healthcare & control rooms), shorter customer ordering cycles reducing near-term visibility, and timing required to realize Healthcare recovery and modality cost-competitiveness (China hub).
Sign In
Buy BCNAF